INDOCO REMEDIES LTD.
P&L
Quarterly Consolidated
vs Q4 FY25
Indoco Remedies Ltd. Achieves 10.3% Growth in Domestic Formulation Business in FY 2024-2025
14 Aug 2025 · 14 Aug 2025, 04:18 pm
Summary
Indoco Remedies Ltd. has achieved a 10.3% growth in its domestic formulation business in FY 2024-2025. The company outpaced the growth of the Indian pharmaceutical market, strengthened its brand leadership, and expanded its footprint. The company also entered into two high-potential therapy segments: dermatologicals and anti-glaucoma products. The Master Manufacturing Plan was completed at most of their facilities to bring in efficiencies and cater to the international market base. The R&D team continues to innovate and develop new products.
Key Highlights
- 1
Indoco Remedies Ltd. achieved a 10.3% growth in its domestic formulation business in FY 2024-2025
- 2
The company outpaced the growth of the Indian pharmaceutical market
- 3
Indoco strengthened its brand leadership and expanded its footprint
- 4
Two new therapy segments entered: dermatologicals and anti-glaucoma products
- 5
Master Manufacturing Plan completed to bring in efficiencies and cater to the international market base
- 6
R&D team continues to innovate and develop new products
Management Comments
Not specified
In the year gone by, the pharmaceutical industry has seen ever-changing regulatory scenarios, global supply-chain constraints, increased R&D costs, US tariff uncertainties and market volatility. These have posed significant disruptions worldwide and have compelled us to rethink strategies and strengthen our operational efficiency.
Not specified
Indoco with its forward thinking policies continues to ensure access to quality and affordable healthcare in India and across the globe. The past year has been a defining one for our India business. We outpaced the growth of the Indian pharmaceutical market, strengthened our brand leadership, and expanded our footprint with purpose and precision.
Informational and educational content only. Not investment advice.